NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/16/2026
Back to search
Official data from USPTO
QETYPRA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
07/16/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
02/16/2022
Registration date
12/12/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/12/2023
Last transaction
07/16/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
FR
Examiner
AGREDA, SAMANTHA LEIGH
Law office
N50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
IPSEN PHARMA S.A.S.
IPSEN PHARMA S.A.S
Representatives
Ben Natter Haug Partners, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in the prevention and the treatment of cancerorphan diseasesimmune disordersliver diseasesbiliary diseasesmetabolic diseasesinflammatory diseasesurological diseasesdisorders and diseases of the reproductive systempuberty diseases or disordersgynecological disordersfertilityacromegalia and tumorshormonal disordersendocrine disordersconnective tissue diseaseblood diseasesgastrointestinal diseases and disordershemophiliagastrointestinal bleeding disordersneurological diseasesmuscle disordersbone disordersskeletal disordersneuromuscular disorderscervical dystoniacerebral palsyspasticityblepharospammigrainebladder pain syndromepainglabellar linesfacial wrinklesasymmetries and defects and conditions of the human skin; Pharmaceutical preparations containing notably botulinum toxinbotulinum toxin-haemagglutin complexbotulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified components of the toxin haemagglutin complex for skin care and the treatment of neurological disorders
Publications
History of USPTO decisions and trademark events.
31 publications found
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
04/02/2026
RNWL
INTERNATIONAL REGISTRATION RENEWED
07/16/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/29/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/13/2024
FIMP
FINAL DISPOSITION PROCESSED
03/13/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
03/12/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
12/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
10/31/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/26/2023
PUBO
PUBLISHED FOR OPPOSITION
09/26/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/13/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/13/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/06/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/06/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/06/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/22/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/19/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/19/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/19/2023
RFNT
REFUSAL PROCESSED BY IB
02/27/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/27/2023
RFRR
REFUSAL PROCESSED BY MPU
01/27/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/10/2022
CNRT
NON-FINAL ACTION WRITTEN
12/09/2022
DOCK
ASSIGNED TO EXAMINER
12/01/2022
MAFR
APPLICATION FILING RECEIPT MAILED
04/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/08/2022
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
04/07/2022
Continuous trademark protection
Get notified about every new filing that threatens QETYPRA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.